Sipatrigine
Alternative Names: 619C89; B 619C; BW 619C89Latest Information Update: 24 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Class Anti-ischaemics
- Mechanism of Action Calcium channel antagonists; Glutamate antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cerebral ischaemia; Stroke
Most Recent Events
- 30 Oct 2001 Suspended - Phase-II for Cerebral ischaemia in United Kingdom (unspecified route)
- 30 Oct 2001 Suspended - Phase-II for Stroke in France (unspecified route)
- 30 Oct 2001 Suspended - Phase-II for Stroke in Germany (unspecified route)